sEphB4-HSA
Phase 3Small molecule
sEphB4-HSA is one of 61 small molecule programs targeting Kaposi Sarcoma. It is currently in Phase 3.
2
Indications
2
Total Trials
2
Active Trials
60
Competitors
Pipeline
Status by Indication[3][1]
Competition
Competitive Landscape
137 competitors in Solid Tumors
#DrugCompanyPhaseTrials
1Keytruda
Merck & Co.Phase 3
Lynparza
AstraZenecaPhase 3
Lenvima
EisaiPhase 3
Taxol
TevaPhase 2
Gemzar
Johnson & JohnsonPhase 2
Opdivo
Bristol-Myers SquibbPhase 2
Beyfortus
BeiGenePhase 2
Yervoy
Bristol-Myers SquibbPhase 2
Fludara
SanofiPhase 2
Camptosar
PfizerPhase 2
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for sEphB4-HSA. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- VVasgene Therapeutics, Inc